丹麦诺维信Novozymes www.novozymes.com.cn  www.novozymes.com
丹麦诺维信公司（Novozymes A/S）成立于1941年,是领导世界酶制剂和微生物领域产品的公司，世界市场份额超过45%，产品销售遍及全球130多个国家。诺维信总部设在哥本哈根，在30个国家建立了分支机构，员工总数5000人。2007年诺维信全球营业收入74.38亿丹麦克朗，净利润10.42亿丹麦克朗。该公司是丹麦在华最大投资企业之一，自1994年起累计在中国投资超过2亿美元，在天津经济技术开发区和北京中关村科技园区分别建立了酶制剂生产基地和中国首家由外商投资设立的生物技术研发中心。位于天津经济技术开发区的诺维信（中国）生物技术有限公司是诺维信集团全球三大酶制剂战略生产基地之一，2008年该公司在天津又新增投资3亿人民币。诺维信公司在江苏太仓投资建设的苏州宏达制酶公司四期扩建工程2008年底前已完工并投入使用，使之成为目前全球最大的酶发酵生产基地，主要生产用于生物乙醇工业使用的酶制剂。诺维信公司从2006年6月开始与中国中粮集团进行第二代生物乙醇的技术合作，通过诺维信提供的酶技术，将玉米秸秆、木质素纤维素等原料变为可发酵糖，再变为工业乙醇。
以粮食和经济作物为原料的第一代燃料乙醇生产从长远看具有规模限制和不可持续性，而利用秸秆、禾草和森林工业废弃物等非食用纤维素生产乙醇，不存在与人争粮的问题，以纤维素为原料的第二代“非粮”生物燃料乙醇是决定未来大规模替代石油的关键。诺维信公司从2001年就开始研究该项技术，目前在生产第二代生物乙醇的酶发酵技术上目前处于世界领先水平，现有150人从事该领域的专门研究，并与包括世界生物能源领先企业美国ICM等50多家相关机构建立了研发联系。诺维信公司在酶领域的技术在2008年开始变得相对成熟，丹麦DONG能源公司今年9月投产的第二代生物乙醇提炼厂就使用了诺维信公司的酶技术。诺维信公司希望能在2010年实现第二代生物乙醇的规模化生产。
诺维信公司非常关注中国能源市场，并希望该技术能在中国发展生物燃料乙醇产业，尤其是第二代“非粮”生物乙醇产业中得到应用，为中国发展清洁能源和节能减排提供技术支持。谢杭生大使向Steen Riisgaard先生通报了当前国内经济形势和应对全球经济衰退的政策措施,以及中国在能源发展领域的政策，对诺维信公司的中国发展战略表示支持，驻丹使馆在此过程中愿提供必要的帮助。

Novozymes is a biotech-based world leader in industrial enzymes and microorganisms. The company produces and sells more than 500 enzyme products in 120 countries. Since 1941, Novozymes has introduced almost every new industrial enzyme on the market, making the company the word’s largest manufacturer of enzymes today.
 Novozymes is the biotech-based world leader in enzymes and microorganisms. We strive towards better business, cleaner environment and better lives. Novozymes is the biotech-based world leader in enzymes and microorganisms. Using nature's own technologies, we continuously expand the frontiers of biological solutions to improve industrial performance in all areas.
Environment-friendly products 
Novozymes' more than 600 products are a key player in the production of thousands of products you use in your everyday life - from the textiles in your clothes to the food you eat.
In more than 40 different industries and 130 countries, our biological solutions improve industrial performance and quality while at the same time saving on water, energy, raw materials and waste.
Solutions for the future 
In partnership with customers, technology leaders and other stakeholders, Novozymes' 4,000 employees use nature's diversity and our advanced biotech platform to make these unique qualities available to businesses everywhere.
We imagine a future where our biological solutions create the necessary balance between better business, cleaner environment and better lives. 
To get there:

We will drive a significant expansion of the market for industrial biotechnology with enzymes and micro organisms as our basis.

We will find new and improved solutions to serve the market for biopharmaceuticals.

We will achieve double digit growth with a leadership position in all markets served.

Customers and partners throughout the world will seek our collaboration because of what we do and how we do it.

People from all over the world will want to work for us because of what we do and how we do it.

Society will be inspired by our work to choose biological solutions as a key part of the future. 
Novozymes to acquire Indian enzyme business
Novozymes acquires Biocon’s enzyme business for an agreed purchase price equivalent to DKK 551 million. Novozymes thereby strengthens its position in India.
Biocon is one of India's leading biotechnology companies, specialising in biopharmaceuticals, contract research, clinical research and enzymes. The company is the leading enzyme player in India, and the enzyme business includes a broad range of industrial enzymes, food additives and process aids. Further, Biocon holds a leading position in the global enzymes market for the juice and wine industries.
“The acquisition of Biocon’s enzyme business provides an important step for Novozymes in strengthening our position on the Indian market, which we believe has an attractive growth potential. The activities of Biocon have a good strategic fit to our existing enzyme business”, says CEO of Novozymes, Steen Riisgaard, “We see several interesting market opportunities combined with synergy potential, making this a very interesting acquisition“, he continues.
AWMB@novozymes.com